[go: up one dir, main page]

EP0379523A1 - Traitement d'infections avec un facteur de necrose des tumeurs - Google Patents

Traitement d'infections avec un facteur de necrose des tumeurs

Info

Publication number
EP0379523A1
EP0379523A1 EP88909650A EP88909650A EP0379523A1 EP 0379523 A1 EP0379523 A1 EP 0379523A1 EP 88909650 A EP88909650 A EP 88909650A EP 88909650 A EP88909650 A EP 88909650A EP 0379523 A1 EP0379523 A1 EP 0379523A1
Authority
EP
European Patent Office
Prior art keywords
tnf
infection
host
infections
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88909650A
Other languages
German (de)
English (en)
Inventor
Kong Teck Chong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of EP0379523A1 publication Critical patent/EP0379523A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • This invention relates to the use of tumor necrosis factor in the prophylactic or therapeutic treatment of infectious diseases.
  • immunomodulating agents 5 inhibited by a variety of immunomodulating agents. These agents may be classified as: 1) crude immunosti ulant of microbial nature
  • examples are ycobacterium boris strain BCG and the killed vaccine of corynebacterium parvum); and 2) chemically defined immunoadjuvants of bacterial origin (examples are 1 ipopolysaccharides). More recently,
  • Cytomegalovi us is one of the most important viral opportunistic infections in AIDS patients. The infection can often lead to severe and sometimes fatal disease, including
  • CMV infection is so closely associated with the AIDS syndromes that the virus has been suspected of contributing to the immunosuppression that characterizes AIDS. See Acquired Immunodeficiency Syndrome (AIDS), ed. J.I. Gall in and A.S.
  • AIDS Acquired Immunodeficiency Syndrome
  • Tumor necrosis factor was first described by Carswell et al., PNAS (USA) (1975) _72_:3666-3670 as an endotoxin-induced serum factor that causes necrosis of chemically transformed tumor cells when 30 growing in mice.
  • Human TNF is known to be cytotoxic to neoplastic cells, and has been produced in recombinant form. See Pennica et al . , Nature (London) (1984) 312:724-729 and Shirai et al., Nature (London) (1985) 313:803-806, Wang et al., Science (1985), 228:149-154.
  • TNF has been reported by Mestan et al., Nature, 323:816-819 (1986), Wong et al . , Nature, 323:819-822 (1986), and Masayoshi et al . ,
  • the present invention is directed to a method for prophylactic or therapeutic treatment of infections in mammalian hosts comprising administering to the host, before or after infection of the host, an effective amount of tumor necrosis factor (TNF) from a mammalian species, wherein the amount of TNF is a sufficient dose to achieve at least a 50% protection of the host.
  • TNF tumor necrosis factor
  • the treatment is prophylactic for viral infections.
  • the term "recombinant” refers to TNF produced by recombinant DNA techniques wherein generally the gene coding for the TNF is cloned by known recombinant DNA technology.
  • the gene showing complementarity to the human TNF cDNA is inserted into a suitable DNA vector such as a bacterial plasmid, preferably an E. coli plasmid, to obtain a recombinant plasmid, and the plasmid is used to transform a suitable host.
  • Tne gene is expressed in the host to produce the recombinant TNF protein.
  • Suitable recombinant plas ids for this purpose include pBR322, pCRl, pMB9 and pSCl.
  • the transformed host may be eucaryotic or procaryotic, preferably a procaryotic host.
  • the term “pharmaceutically acceptable” refers to a carrier medium that does not interfere with the effectiveness of the biological activity of the active ingredient and that is not toxic to the hosts to which it is administered.
  • prophylactic or therapeutic treatment refers to administration to the host of the TNF either before or after infection. If the TNF is administered prior to exposure to the infecting agent, the treatment is prophylactic (i.e., it protects the host against infection), whereas if administered after infection, the treatment is therapeutic (i.e., it combats the existing infection). Preferably, the dose is administered from 18 hours before infection for prophylactic treatment and in early as well as in later phase of infection for therapeutic treatment.
  • infections refers to any kind of infectious disease, including those caused by bacteria, fungi, viruses, protozoa or parasites.
  • bacterial infections include j ⁇ _ aeruginosa, E. coli tetanus, Mycobacterium species, Streptococcal strains, diphtheria and Salmonella.
  • fungal infections include cryptococcosis, histoplasmosis, and other infections due to Candida species.
  • viral infections include Hepatitis A, recurrent Herpes Simplex, AIDS, Herpes Zoster, influenza, cytomegalovirus (CMV), and rhinoviruses.
  • the infection is viral, more preferably Herpes Simplex or CMV, or the infection is bacterial, more preferably Gram-negative, and most preferably P. aeruginosa and E. coli infection.
  • the method of this invention involves administering to a mammalian host, preferably a human host, an effective amount of TNF.
  • the adm ⁇ nistration(s) may take place by any suitable technique, preferably parenteral administration.
  • parenteral administration include intravenous, intraarterial , intramuscular, and intraperitoneal , with intravenous being Dreferre .
  • the dose and dosage regimen will depend mainly on whether the TNF is being administered for therapeutic or prophylactic purposes, the type of infection, the patient, and the patient's history.
  • the amount must be effective to achieve a protection level of at least 50%, preferably at least 70%; dosages which do not achieve this minimal level of effectiveness may not be employed.
  • the doses may be single doses or multiple doses over a period of several days, but single doses are preferred.
  • a protection level of at least 50% means that at least 50% of the treated hosts exhibit improvement against the infection, including but not limited to improved survival rate, more rapid recovery, or improvement or elimination of symptoms.
  • the preferred dosage of TNF is about 0.4- 2.0- ⁇ .g per kg body weight of TNF per dose.
  • the TNF will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion), preferably in a pharmaceutically acceptable carrier medium that is inherently non- toxic and non-therapeutic or non- prophylactic.
  • a pharmaceutically acceptable carrier medium that is inherently non- toxic and non-therapeutic or non- prophylactic.
  • examples of such vehicles include saline, Ringer's solution, dextrose solution, mannitol, and normal serum albumin.
  • Non- aqueous vehicles such as fixed oils and ethyl oleate may also be used.
  • the carrier medium may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives.
  • the TNF will typically be formulated in such carriers at a concentration of about 0.1 mg/ml to 100 mg/ l , preferably 0.2 to 1 mg/ml.
  • the TNF employed herein may be obtained from tissue cultures or by recombinant techniques, and from any mammalian source such as, e.g., mouse, rat, rabbit, ' primate, pig, and human.
  • the TNF is derived from a human source and more preferably is a human recombinant TNF.
  • the recombinant human TNF may be obtained as described by Pennica et al . , Nature, _312_:724-729 t 1 - 984 ). Yamada et al . , J. Biotechnology, (1985) 2:141-153; Wang et al . , Science (1985), 228:149- 154; EP 155,549 published September 29, 1985, EP 158,286 published October 16, 1985; EP 168,214 published January 15, 1986; and PCT US85/01921 published April, 1986.
  • the recombinant rabbit TNF may be obtained as described in EP 146,026 published June 26, 1985 and EP 148,311 published July 17, 1985.
  • the TNF is a human TNF mutein that is N-terminally deleted, preferably wherein the first eight amino acid residues have been deleted, using the procedure described in U.S. Patent No. 4,677,063 issued June 30, 1987 or the TNF is a cysteine-depleted mutein described in copending U.S. Serial No. 698,939 filed February 7, 1985 and in U.S. Patent No. 4,518,584, supra (for IL-2 but applicable to TNF).
  • % protection is % survival rate, which is only one test of many which may be employed to determine the extent of protection in the host.
  • % survival rate is only one test of many which may be employed to determine the extent of protection in the host.
  • all parts for solids are by weight and all percentages for liquids and gases are by volume, unless otherwise noted, and all temperatures are given in degrees Celsius.
  • a mutein of human TNF having the first eight amino acids deleted from the N-terminus was . prepared as described in U.S. Patent No. 4,677,063. Briefly, TNF was induced from HL-60 cells and purified and sequenced. Then an intronless sequence encoding human TNF was prepared by producing enriched mRNA, constructing a cDNA library, selecting a probe and probing the library to recover the sequence. Then an ATG start codon was introduced immediately preceding the GTC sequence encoding N-terminal valine of the mature protein by site- directed mutagenesis. Clones were selected and strands li gated into expression vectors to obtain procaryotic expression of the mutein. The mutein was then suspended in a formulation buffer.
  • IL-2 Preparation
  • the recombinant IL-2 employed in this example was des-ala ⁇ IL-2 ser 25 - T e amino acid sequence of this IL-2 differs from the amino acid sequence of native human IL-2 in that it lacks the initial alanine of the native molecule, and the cysteine at position 125 has been changed to serine.
  • Samples of £___ coli that produce this IL-2 have been deposited by Cetus Corporation in the American Type Culture Collection, 12301 Pa kl awn Drive, Rockv lle, Md, USA on September 26, 1983 under accession number 39,452 and on March 6, 1984 under accession number 39,626 under the provisions of the Budapest Treaty.
  • the IL-2 was processed and purified as described in the text and Figure 1 of U.S. Patent No. 4,604,377, the disclosure of which is incorporated herein by reference, except that the oxidation was carried out using copper chloride, as described in U.S. Patent No. 4,572,798 rather than o-iodosobenzoate.
  • the IL-2 was recovered from the chromatography step(s) it was lyophilized and resuspended in a neutral aqueous buffer containing the reducing agent (DTT) to keep the IL-2 in a reduced state and a sol ubil zing agent to keep it in solution.
  • the purity of the recombinant IL-2 after the chromatography step(s) was at least about 95% and the IL-2 contained less than about 0.02 ng/ml endotoxin as determined by the Limulus amebocyte assay.
  • the purified IL-2 was formulated at a concentration of 0.3 mg/ml with 50 mg/ml mannitol.
  • Bacteria E. col i SM18 a type 02 clinical isolate from a bacteremic patient at Saint Mary's Hospital, San Francisco, CA, was cultured overnight in brain-heart infusion broth (Difco Laboratories, Detroit,
  • mice randomly distributed into groups of 15, were injected intraperitoneally in a single dose with either saline, 0.01 g per dose of recombinant TNF described above, 10,000 units per dose of recombinant IL-2 described above, or a single dose of the TNF (at O.OLug) followed immediately by a single dose of the IL-2 (at 10,000 units).
  • mice were injected intraperitoneally with the LD 100 (6 x 10 7 cfu) of _E ⁇ _ coli SM18 described above per mouse.
  • the LD ⁇ QQ represents the minimum number of bacteria necessary to kill all the mice within a group.
  • Table I show mortality rates after seven days.
  • mice were observed daily and mortality was recorded for 4 to 7 days.
  • mice were treated with 2.0 ⁇ -g/kg of the TNF described in Example 1, intraperitoneally. Two doses were administered, at one day before and at four hours before infection challenge with herpes simplex virus at 1 x 10 pfu per mouse. The results showed that the mice treated with TNF showed significantly greater survival than saline- treated control animals (p 0.05). Thus, TNF may be used alone or in combination with another lymphokine in the treatment of viral infection.
  • the present invention is seen to provide an effective therapeutic and prophylactic composition to combat infections that contains TNF.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP88909650A 1987-07-31 1988-07-20 Traitement d'infections avec un facteur de necrose des tumeurs Withdrawn EP0379523A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8030287A 1987-07-31 1987-07-31
US80302 1987-07-31

Publications (1)

Publication Number Publication Date
EP0379523A1 true EP0379523A1 (fr) 1990-08-01

Family

ID=22156521

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88909650A Withdrawn EP0379523A1 (fr) 1987-07-31 1988-07-20 Traitement d'infections avec un facteur de necrose des tumeurs

Country Status (5)

Country Link
EP (1) EP0379523A1 (fr)
JP (1) JPH02504391A (fr)
AU (1) AU2624988A (fr)
IL (1) IL87182A0 (fr)
WO (1) WO1989000805A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1850892B2 (fr) 2005-01-24 2023-04-19 Antares Pharma, Inc. Injecteur a seringue preremplie assiste d'une aiguille
ES2988196T3 (es) 2009-03-20 2024-11-19 Antares Pharma Inc Sistema de inyección de agentes peligrosos
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
DK2822618T3 (da) 2012-03-06 2024-01-22 Antares Pharma Inc Forfyldt nål med brudkraftfunktion
EP3572108A1 (fr) 2013-03-11 2019-11-27 Antares Pharma, Inc. Injecteur de dose avec système à pignon

Also Published As

Publication number Publication date
IL87182A0 (en) 1988-12-30
JPH02504391A (ja) 1990-12-13
AU2624988A (en) 1989-03-01
WO1989000805A2 (fr) 1989-02-09

Similar Documents

Publication Publication Date Title
CA1290248C (fr) Traitement d'infections a l'aide de lymphochines
US5370870A (en) Method for protection against reactive oxygen species
US6719969B1 (en) Treatment of liver disease and injury with CXC chemokines
EP0373679A2 (fr) Formulations stabilisées à base de protéines hydrophobes
US5437863A (en) Method of enhancing the growth of gut epithelial cells by administration of a cytokine such as interleukin II
JP2000504029A (ja) 感染症の治療のためのＩＬ―１２およびＩＦＮαの使用
US5578568A (en) Method of treating conditions associated with intestinal ischemia/reperfusion
Alexander et al. Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor.
AU625807B2 (en) Uses of recombinant colony stimulating factor-1
US6013631A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
CA2092718C (fr) Utilistion d'agents protecteurs contre des especes reagissant a l'oxygene
EP0379523A1 (fr) Traitement d'infections avec un facteur de necrose des tumeurs
US5725850A (en) Use of CSF-1 to treat tumor burden
EP0549702B1 (fr) Utilisation du facteur stimulateur de colonies de type 1 recombine
WO2001010899A2 (fr) Traitement de maladies et de lesions hepatiques avec des chimiokines cxc
EP0273778A2 (fr) Comportement synergique de csf-1 et G-csf
EP1033997B1 (fr) Technique visant a mobiliser des cellules souches hematopoietiques
EP1185292B1 (fr) Utilisation d'interleukine-11 dans le traitement du choc hemorragique
KR20150061030A (ko) 소 과립구 콜로니 자극 인자 및 그의 변이체를 위한 제제
WO1990001328A1 (fr) Fnt et ses compositions dans le traitement ou la prophylaxie de l'hepatite b
CA1320129C (fr) Action synergique du csf-1 et du g-csf
AU661463C (en) Use of protective agents against reactive oxygen species
JPH04360840A (ja) 血小板減少症治療剤
WO1994023739A1 (fr) PROCEDE DE REDUCTION DE LA TOXICITE DE COMPOSITIONS THERAPEUTIQUES AU MOYEN DE THYMOSINE β¿4?

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920201